TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 will be available from January 2023. […]
29/11/2022
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
Our news
News
29/11/2022
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
> READ
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
> READ
News
24/08/2023
Alliance Promotion Microbiote applauds the new legislation securing stool collection in France
> READ
Alliance Promotion Microbiote applauds the new legislation securing stool collection in France
> READ
News
26/04/2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
> READ
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
> READ
> See all news